Bladder Cancer Recurrence Prediction via Multi-Biomarker Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for predicting the recurrence and progression of bladder cancer lack reliable biomarkers, leading to inadequate monitoring and treatment strategies, particularly for nonmuscle-invasive bladder cancer, which has a high propensity for recurrence and requires lifelong surveillance.
Innovation Solution
A method involving the determination and comparison of specific biomarkers, such as those listed in Tables 1, 2, and 3, in patient samples to predict the risk of recurrence and progression of bladder cancer, utilizing techniques like antibody microarrays and statistical analysis to identify statistically significant differences associated with cancer recurrence.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current biomarker methods are used for predicting bladder cancer recurrence, then the detection can be performed with existing techniques, but the prediction accuracy and reliability are insufficient
Solution Approach 1:
The patent combines multiple previously described biomarkers (Bcl-2, P53, caspase-3, and other apoptosis markers) into a single integrated detection method. By measuring multiple biomarkers simultaneously rather than individually, the method achieves higher prediction accuracy and reliability for bladder cancer recurrence, overcoming the limitations of single biomarker approaches.
2Measurement precision
If multiple biomarkers are combined for prediction, then the prediction accuracy improves, but the complexity of detection methods increases
Solution Approach 1:
The patent develops a universal detection method that can simultaneously measure multiple biomarkers (Bcl-2, P53, caspase-3, and other apoptosis markers) using a single integrated assay platform. This multi-functional approach allows the detection system to perform multiple measurements in one procedure, improving prediction accuracy while minimizing the increase in operational complexity.
3Adaptability or versatility
If apoptosis markers are used for prediction, then the biological relevance is high, but the detection accuracy for individual mutations is inconvenient and limited
Solution Approach 1:
The patent merges the detection of multiple apoptosis-related biomarkers (Bcl-2, P53, caspase-3) into a unified detection system. By combining these biologically relevant markers into a single multi-marker assay, the method maintains high biological relevance while achieving improved detection accuracy through the cumulative information from multiple markers, overcoming the limitations of individual mutation detection.
Data Source
AI summary
The present invention pertains to the field of cancer prediction. Specifically, it relates to a method for predicting the risk of recurrence of bladder cancer in a subject after treatment of bladder cancer comprising the steps of determining the amount of at least one biomarker selected from the biomarkers shown in Table, and comparing the amount of said at least one biomarker with a reference amount for said at least one biomarker, whereby the risk of recurrence of bladder cancer is to be predicted. The present invention also contemplates a method for identifying a subject being in need of a further bladder cancer therapy. Encompassed are, furthermore, diagnostic devices and kits for carrying out said methods.